Produkte von Innaxon
Innaxon ist ein Unternehmen mit Sitz in Tewkesbury, Vereinigtes Königreich, das sich auf angeborene Immunität, Toll-like Rezeptor (TLR)-Agonisten und niedermolekulare Inhibitoren konzentriert. Innaxon entwickelt und produziert definierte "Immunoceuticals" von höchster Aktivität und Reinheit für präklinische Forschungs- und Entwicklungsanwendungen für Impfstoffadjuvantien und Immuntherapie. Die einzigartigen biologischen und synthetischen TLR-Liganden von Innaxon sind gut charakterisierte und wirksame biologische Reaktionsmodifikatoren für unangemessene oder unverhältnismäßige Immunreaktionen.
Mehr Informationen unter: www.adipogen.com/innaxon
Für die Filterung wurden keine Ergebnisse gefunden!
iODN (inhibitory ODN) (ttaggg)4 Endotoxin-free (sterile)
Artikelnummer: IAX-200-051-C100
Potent sequence of an inhibitory ODN for in vivo use in rodents (100-300 µg per injection), prototype class II, inhibits STAT signaling, independent of TLR signaling. Negative control: Neutral-ODN (Cat. No.: IAX-200-202).
| Schlagworte: | Inhibitory ODN (iODN): Class II |
| Anwendung: | STAT signaling inhibitor |
| MW: | 8288 D |
ab 176,00 €
Neutral-ODN (Control for iODNs) Endotoxin-free (sterile)
Artikelnummer: IAX-200-202-M001
Negative control GpC ODN for in vivo use in rodents (50-150 µg per injection). As active compound use CpG ODN 1585 (Cat. No.: IAX-200-003). For negative control without agonistic nor antagonistic activity: Neutral-ODN (Cat. No.: IAX-200-202).
| Anwendung: | Negative Control for ODN 1585 (IAX-200-003) |
| MW: | 4821 D |
ab 176,00 €
ODN 2243 (Control for ODN 2216) Endotoxin-free (sterile)
Artikelnummer: IAX-200-205-C100
Negative control GpC ODN for in vivo use in rodents (50-150 µg per injection). As active compound use CpG ODN 2216 (Cat. No.: IAX-200-005). For negative control without agonistic nor antagonistic activity: Neutral-ODN (Cat. No.: IAX-200-202).
| Anwendung: | Negative Control for ODN 2216 (IAX-200-005) |
| MW: | 6684 D |
176,00 €
ODN 2137 (Control for ODN 2006) Endotoxin-free (sterile)
Artikelnummer: IAX-200-206-C100
Negative control GpC ODN for in vivo use in rodents (50-150 µg per injection). As active compound use CpG ODN 2006 (Cat. No.: IAX-200-006). For inegative control without agonistic nor antagonistic activity: Neutral-ODN (Cat. No.: IAX-200-202).
| Anwendung: | Negative Control for ODN 2006 (IAX-200-006) |
| MW: | 6684 D |
176,00 €
IAXO-102 (CD14/TLR4 Antagonist) (synthetic)
Artikelnummer: IAX-600-002-M001
Described to interfere with human, rat and mouse TLR4/CD14 signaling, other species not tested. Optimal working concentration depends upon the type, purity and concentration and of TLR4 ligand, carrier protein such as LPS-binding protein (LBP), soluble and membrane-bound CD14, the presence of TLR4 co-receptors (e.g....
| Schlagworte: | Methyl 6-deoxy-6-amino-2,3-di-O-tetradecyl-?-D-glucopyranoside |
| Anwendung: | CD14/TLR4 Antagonist |
| CAS | 1115270-63-7 |
| MW: | 585.94 D |
358,00 €
IAXO-103 (CD14/TLR4 Antagonist) (synthetic)
Artikelnummer: IAX-600-003-M001
Described to interfere with human, rat and mouse TLR4/CD14 signaling, other species not tested. Optimal working concentration depends upon the type, purity and concentration and of TLR4 ligand, carrier protein such as LPS-binding protein (LBP), soluble and membrane-bound CD14, the presence of TLR4 co-receptors (e.g....
| Schlagworte: | N-(3,4-bis-Tetradecyloxy-benzyl)-N-cyclopentyl-N,N-dimethylammonium iodide |
| Anwendung: | CD14/TLR4 Antagonist |
| CAS | 1202208-36-3 |
| MW: | 755.98 D |
358,00 €
Mini-iODN (inhibitory ODN) Endotoxin-free (sterile)
Artikelnummer: IAX-200-053-C100
Potent sequence of an inhibitory ODN for in vivo use in rodents (50-150 µg per injection): prototype class I, may also affect TLR7 and TLR8 signaling. egative control: Neutral-ODN (Cat. No.: IAX-200-202).
| Schlagworte: | Inhibitory ODN (iODN): Class I |
| Anwendung: | TLR9 competitor |
| MW: | 3584 D |
176,00 €
Mega-iODN (inhibitory ODN) Endotoxin-free (sterile)
Artikelnummer: IAX-200-054-C100
Particularly potent sequence of an inhibitory ODN for in vivo use in rodents (50-150µg per injection): based on class I (ODN H154) and class II (ODN A151) sequences to combine inhibitory activity on TLRs and STAT signaling. Negative control: Neutral-ODN (Cat. No.: IAX-200-202).
| Schlagworte: | Inhibitory ODN (iODN): Class I/II |
| Anwendung: | TLR9 competitor |
| MW: | 5894 D |
176,00 €
Duo-iODN (inhibitory ODN) Endotoxin-free (sterile)
Artikelnummer: IAX-200-055-C100
Potent sequence of an inhibitory ODN for in vivo use in rodents (50-150µg per injection): prototype class I that also inhibits TLR7 signaling. Negative control: Neutral-ODN (Cat. No.: IAX-200-202).
| Schlagworte: | Inhibitory ODN (iODN): Class I |
| Anwendung: | TLR9 competitor |
| MW: | 5867 D |
ab 176,00 €
ODN 2218 (Control for ODN 1585) Endotoxin-free (sterile)
Artikelnummer: IAX-200-203-C100
Negative control GpC ODN for in vivo use in rodents (50-150 µg per injection). As active compound use CpG ODN M362 (Cat. No.: IAX-200-004). For negative control without agonistic nor antagonistic activity: Neutral-ODN (Cat. No.: IAX-200-202).
| Anwendung: | Negative Control for ODN M362 (IAX-200-004) |
| MW: | 8073 D |
176,00 €
ODN M383 (Control for ODN M362) Endotoxin-free (sterile)
Artikelnummer: IAX-200-204-C100
Negative control GpC ODN for in vivo use in rodents (50-150 µg per injection). As active compound use CpG ODN 2216 (Cat. No.: IAX-200-005). For negative control without agonistic nor antagonistic activity: Neutral-ODN (Cat. No.: IAX-200-202).
| Anwendung: | Negative Control for ODN 2216 (IAX-200-005) |
| MW: | 8073 D |
176,00 €
Lipodisq Control Sterile Solution
Artikelnummer: IAX-700-100-L001
A nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane...
| Schlagworte: | Detergent-free Nano-formulation made of Styrene-maleic Acid Lipid Particles (SMALP) |
| Anwendung: | Nanoparticle (11-40nm) drug delivery system |
296,00 €